ARS Pharmaceuticals Valuation After Single Day Share Price Jump of 19.3%

ARS Pharmaceuticals (SPRY) shares surged 19.3% after a strong single-day move, with gains over the past week, month, and quarter. The company's 3-year total shareholder return is 75.3%. The stock is undervalued compared to the US$28.83 analyst target and intrinsic value estimates, with a fair value of $28.83. The long-term demand for needle-free emergency therapies like Neffy is driving sustained top-line revenue expansion. However, any stumble in Neffy adoption or pricing pressure could challenge those fair value assumptions.